UBS keeps a Buy rating and $435 price target on shares of Elevance Health (ELV), telling investors in a research note that the firm believes the appropriate jump-off point EPS is $29.27. The firm thinks 2026 EPS could land “in the low to mid 30s,” but will need to overcome some items.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $297 from $492 at Baird
- Elevance Health’s (ELV) Earnings Blunder Entices Bullish Stock Option Traders
- Insiders Are Betting Big on These 2 Stocks – Should You Follow Their Lead?
- Elevance Health price target lowered to $327 from $358 at Barclays
- Target downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls